Skip to main content
●+254 119 023975 support@dnalabskenya.com
Patient Portal LoginB2B / Doctor Portal
DNA LabsKenya
Medical information Clinical review pending

Genetic Testing

GARS1 Gene CMT2D Genetic Test

The GARS1 Gene CMT2D NGS Genetic DNA Test identifies mutations in the GARS1 gene associated with Charcot-Marie-Tooth disease type 2D (CMT2D), a neurological disorder. This test uses Next Generation Sequencing (NGS) technology for accurate genetic analysis.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (usually collected in an EDTA tube). Confirm specific requirements with the laboratory before booking.
Results
Results are typically available within 3 to 4 weeks. Confirm with the laboratory before booking.
Preparation
No special preparation is typically required for this blood test. However, confirm with the laboratory for any specific instructions.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the GARS1 Gene CMT2D Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us
01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Symptoms suggestive of Charcot-Marie-Tooth disease (e.g., muscle weakness, atrophy, sensory loss).
  • ✓Family history of CMT2D or related neurological disorders.
  • ✓Unexplained peripheral neuropathy.
  • ✓Genetic evaluation recommended by a neurologist.
  • ✓Confirmation of a suspected GARS1-related disorder.
02

In plain language

What this test helps you understand

This test helps identify mutations in the GARS1 gene, which are associated with Charcot-Marie-Tooth disease type 2D (CMT2D). Identifying these mutations can aid in the diagnosis of CMT2D, a type of peripheral neuropathy, and help guide management strategies.
The GARS1 Gene CMT2D NGS Genetic DNA Test is a diagnostic tool used to identify mutations in the GARS1 gene. Mutations in this gene are linked to Charcot-Marie-Tooth disease type 2D (CMT2D), a condition affecting peripheral nerves. This test utilizes advanced Next Generation Sequencing (NGS) technology to provide a detailed analysis of the GARS1 gene. Understanding genetic factors can be important for diagnosing and managing neurological conditions. This test helps healthcare providers understand the potential genetic basis of neurological symptoms. It is particularly relevant for individuals with symptoms suggestive of CMT2D or a family history of related neurological disorders.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is typically required for this blood test. However, confirm with the laboratory for any specific instructions.
SampleBlood sample (usually collected in an EDTA tube). Confirm specific requirements with the laboratory before booking.
MethodologyNext Generation Sequencing (NGS) is used to analyze the GARS1 gene for mutations.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically analyzes the GARS1 gene. It may not detect mutations in other genes that can cause similar symptoms. A negative result does not completely rule out a genetic cause for the condition. Interpretation requires clinical correlation.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

CMT2D is a type of inherited peripheral neuropathy, a condition affecting the nerves outside the brain and spinal cord, leading to symptoms like muscle weakness and sensory loss.
Individuals experiencing symptoms of CMT, those with a family history of CMT2D, or patients referred by a neurologist for genetic evaluation may benefit from this test.
The test involves analyzing a blood sample using Next Generation Sequencing (NGS) technology to look for mutations in the GARS1 gene.
A healthcare provider or genetic counselor will interpret the results in the context of your clinical history and family history. They will explain the significance of any findings.
Results are typically available within 3 to 4 weeks, but this can vary. Confirm the current turnaround time with the laboratory.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Beta CTx Beta Crosslaps Collagen Type 1 C-Telopeptide Test

The Beta CTx test measures bone resorption markers to help assess bone health and osteoporosis risk.

Learn more →

Bcell Rearrangement Detection Test

The Bcell Rearrangement Detection Test helps diagnose leukemia by identifying genetic changes in B cells. It's a key tool for hematologists and oncologists.

Learn more →

Dpd Gene Mutations 5Fu Toxicity Detection Test

This genetic test identifies mutations in the DPD gene, helping predict the risk of severe side effects from the chemotherapy drug 5-fluorouracil (5FU).

Learn more →

Ganciclovir Resistance Detection Test

This test checks for genetic changes in the cytomegalovirus (CMV) that may make it resistant to the antiviral medication Ganciclovir. It helps guide treatment decisions, especially for patients with weakened immune systems.

Learn more →
Chat on WhatsApp